The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Novel Phage Lysin Capable of Killing the Multidrug-Resistant Gram-Negative Bacterium Acinetobacter baumannii in a Mouse Bacteremia Model
Open accessAbstract
Acinetobacter baumannii , a Gram-negative multidrug-resistant (MDR) bacterium, is now recognized as one of the more common nosocomial pathogens. Because most clinical isolates are found to be multidrug resistant, alternative therapies need to be developed to control this pathogen. We constructed a bacteriophage genomic library based on prophages induced from 13 A. baumannii strains and screened it for genes encoding bacteriolytic activity. Using this approach, we identified 21 distinct lysins with different activities and sequence diversity that were capable of killing A. baumannii . The lysin (PlyF307) displaying the greatest activity was further characterized and was shown to efficiently kill (>5-log-unit decrease) all tested A. baumannii clinical isolates. Treatment with PlyF307 was able to significantly reduce planktonic and biofilm A. baumannii both in vitro and in vivo . Finally, PlyF307 rescued mice from lethal A. baumannii bacteremia and as such represents the first highly active therapeutic lysin specific for Gram-negative organisms in an array of native lysins found in Acinetobacter phage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Bacterial competition: surviving and thriving in the microbial jungle
Hibbing, M. E., Fuqua, C., Parsek, M. R., & Peterson, S. B. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2259 · Cited by 2,689
A bacteriolytic agent that detects and kills Bacillus anthracis
Schuch, R., Nelson, D., & Fischetti, V. A. (2002) · Nature · doi:10.1038/nature01026 · Cited by 656
Self-citationHas the era of untreatable infections arrived?
Livermore, D. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp255 · Cited by 620
Rapid Killing of Streptococcus pneumoniae with a Bacteriophage Cell Wall Hydrolase
Loeffler, J. M., Nelson, D., & Fischetti, V. A. (2001) · Science · doi:10.1126/science.1066869 · Cited by 517
Self-citationCurrent control and treatment of multidrug-resistant Acinetobacter baumannii infections
Karageorgopoulos, D. E., & Falagas, M. E. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70279-2 · Cited by 446
Engineered Endolysin-Based “Artilysins” To Combat Multidrug-Resistant Gram-Negative Pathogens
Briers, Y., Walmagh, M., Van Puyenbroeck, V., Cornelissen, A., Cenens, W., Aertsen, A., Oliveira, H., Azeredo, J., Verween, G., Pirnay, J.-P., et al. (2014) · mBio · doi:10.1128/mbio.01379-14 · Cited by 421
Survival of Acinetobacter baumannii on dry surfaces
Wendt, C., Dietze, B., Dietz, E., & Rüden, H. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.6.1394-1397.1997 · Cited by 400
Acinetobacter infection – an emerging threat to human health
Visca, P., Seifert, H., & Towner, K. J. (2011) · IUBMB Life · doi:10.1002/iub.534 · Cited by 324
Seifert, H., Dijkshoorn, L., Gerner-Smidt, P., Pelzer, N., Tjernberg, I., & Vaneechoutte, M. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.11.2819-2825.1997 · Cited by 322
Cited by
Phage therapy: An alternative to antibiotics in the age of multi-drug resistance
Lin, D. M., Koskella, B., & Lin, H. C. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i3.162 · Cited by 1,135
Alternatives to antibiotics—a pipeline portfolio review
Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V. A., Foster, S., Gilmore, B. F., Hancock, R. E. W., Harper, D., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00466-1 · Cited by 848
Self-citationFederici, S., Kredo-Russo, S., Valdés-Mas, R., Kviatcovsky, D., Weinstock, E., Matiuhin, Y., Silberberg, Y., Atarashi, K., Furuichi, M., Oka, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.07.003 · Cited by 542
Genetically Engineered Phages: a Review of Advances over the Last Decade
Pires, D. P., Cleto, S., Sillankorva, S., Azeredo, J., & Lu, T. K. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00069-15 · Cited by 427
Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals
Ibrahim, S., Al-Saryi, N., Al-Kadmy, I. M. S., & Aziz, S. N. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06690-6 · Cited by 388
Metadata
- Authors
- Lood, R., Winer, B. Y., Pelzek, A. J., Diez-Martinez, R., Thandar, M., Euler, C. W., Schuch, R., & Fischetti, V. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2015-04
- Volume
- 59
- Issue
- 4
- Pages
- 1983-1991
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2159398380
- Cited by
- 272
- References
- 30
- FWCI
- 17.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Phage Lysin Capable of Killing the Multidrug-Resistant Gram-Negative Bacterium Acinetobacter baumannii in a Mouse Bacteremia Model. https://app.cochat.ai/papers/10.1128/aac.04641-14
- The paper
- Lood, R., Winer, B. Y., Pelzek, A. J., Diez-Martinez, R., Thandar, M., Euler, C. W., Schuch, R., & Fischetti, V. A. (2015). Novel Phage Lysin Capable of Killing the Multidrug-Resistant Gram-Negative Bacterium Acinetobacter baumannii in a Mouse Bacteremia Model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.04641-14
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.